REMINDER: Early Roche Axelios & Cross‑Platform Insights – Wellcome Sanger

Research evidence excerpt

REMINDER: Early Roche Axelios & Cross‑Platform Insights – Wellcome Sanger

USA | Life Science Tools & Diagnostics EquityMayResearch22, 2026

REMINDER: Early Roche Axelios & Cross-

Platform Insights – Wellcome Sanger

Please join us TODAY, Friday, May 22nd at 9 am ET for an expert call and

perspective on the early access experience with Roche's SBX Axelios platform

with Dr. Michael Quail, Ph.D. at the Wellcome Trust Sanger Institute. Key topics

will include differentiation and use across the big sequencing players (Roche

SBX, Illumina, Ultima, Element, etc.), the translational and clinical landscape for

NGS, and more. Please register here.

Event Details (Event will NOT be recorded)

Date: TODAY, Friday, May 22nd, 9:00 AM ET

Host: Tycho Peterson, Jefferies Life Science Tools and Diagnostics

PLEASE REGISTER HERE

Discussion Topics:

Early access experience with the Roche Axelios SBX system and real-world usage around•

scale, workflow efficiency, sensor re-use, and other topics

Spec-level and usability comparison across sequencing platforms (Illumina, Roche, Ultima,•

Element, etc.) to understand where sensitivity, throughput, cost, etc. influence platform choice

Emerging landscape for clinical and translational-scale projects (e.g., perturb-seq, multiomic•

workflows) and how new technologies are shifting study design and other workflows

Appetite for larger-scale sequencing programs and multi-instrument capital purchases,•

expectations for future trends in the sequencing landscape overall

Relevant tickers: ILMN, ROP-SW, TXG, BRKR, PACB, TMO, and others

Speaker Biography

Dr. Michael Quail is Principal Scientist of R&D Sequencing at the Wellcome Trust Sanger Institute

in the UK, an early access site for Roche SBX Axelios. He has been in his managing role at Sanger